Table 2.
Correlation of PD-L1 expression with clinicopathological factors in HER2-positive breast cancer.
| PD-L1 expression | N | p | |||
|---|---|---|---|---|---|
| Negative | Positive | ||||
| TILs | High | 6 (26.1%) | 17 (73.9%) | 23 | <0.0001 |
| Intermediate | 34 (91.9%) | 3 (8.1%) | 37 | ||
| Low | 64 (97.0%) | 2 (3.0%) | 66 | ||
| CD8-positive TILs | High | 65 (74.7%) | 22 (25.3%) | 87 | 0.00087 |
| Low | 30 (100.0%) | 0 (0.0%) | 30 | ||
| ER | Negative | 62 (80.5%) | 15 (19.5%) | 77 | 0.45 |
| Positive | 42 (85.7%) | 7 (14.3%) | 49 | ||
| PgR | Negative | 74 (81.3%) | 17 (18.7%) | 91 | 0.56 |
| Positive | 30 (85.7%) | 5 (14.3%) | 35 | ||
| Ki67 | High (≥30%) | 70 (77.8%) | 20 (22.2%) | 90 | 0.36 |
| Low (<30%) | 34 (94.4%) | 2 (5.6%) | 36 | ||
| Histological grade | Grade 3 | 85 (79.4%) | 22 (20.6%) | 107 | 0.043 |
| Grade 1/2 | 19 (100.0%) | 0 (0.0%) | 19 | ||
| Clinical tumor size | cT 3/4 | 38 (86.4%) | 6 (13.6%) | 44 | 0.41 |
| cT 1/2 | 66 (80.5%) | 16 (19.5%) | 82 | ||
| Clinical nodal status | Positive | 68 (80.0%) | 17 (20.0%) | 85 | 0.28 |
| Negative | 36 (87.8%) | 5 (12.2%) | 41 | ||
Abbreviations: PD-L1, programmed death-ligand 1; TILs, tumor-infiltrating lymphocytes; ER, estrogen receptor; PgR, progesterone receptor HER2, human epidermal growth factor receptor 2.